Funding secured, deal in focus
ImmuPharma (LSE:IMM) reported interim results on 15 September 2026 for the six months to 30 June 2026, highlighting progress on its two lead assets after a fundraising in April. The drug developer has said its priority is to secure a commercial deal for its autoimmune candidate P140 during 2026, while advancing its glucagon prodrug, Kapiglucagon, towards first-in-human studies.
What the company does
ImmuPharma is a specialist drug discovery and development company. Its lead asset is P140, also known as Lupuzor or forigerimod, a peptide being developed for autoimmune and inflammatory diseases. Kapiglucagon is a wholly owned glucagon prodrug designed to allow stable liquid formulations, mainly for dual-hormone artificial pancreas systems used in type 1 diabetes. The company also has two preclinical anti-infective programmes, BioAMB and BioCIN. Tim McCarthy is chairman.
Latest developments
At a general meeting on 7 April 2026, shareholders approved a £6m subscription by Lanstead Capital Investors at 6p per share and a retail offer of about £468,000. The Lanstead investment is linked to a sharing agreement under which the cash ImmuPharma ultimately receives depends on its share price against an 8p benchmark, with settlements running until December 2027. At the time, directors expected the funds to provide a cash runway to at least the second half of 2028, assuming full receipts.
In March 2026 the company received its first combined search and examination report on a UK patent application for P140, and after the period end it filed an international Patent Cooperation Treaty application including data from its Type M precision medicine work, which aims to identify patients more likely to respond. Academic studies reported early findings in glioblastoma and in a preclinical liver disease model, though ImmuPharma says autoimmune disease remains its focus. For Kapiglucagon, a development plan was approved in the first half and specialist partners selected.
Financial picture
The operating loss narrowed to £1.07m from £1.23m. However, the loss for the period widened to £4.70m, mainly because of a £3.36m fair value loss on the derivative asset linked to the Lanstead arrangement, which can move in either direction with the share price. Cash was £0.70m at 30 June 2026 and net assets were £1.82m. The company does not pay a dividend.
Sector and index context
ImmuPharma is one of many early-stage life sciences companies in the FTSE AIM All Share Index. Smaller biotech firms on AIM often depend on partnering deals to fund late-stage trials, and investor sentiment towards the sector can swing sharply with funding conditions. Lanstead-style sharing agreements are used by a number of AIM companies but tie funding to share price performance.
Key risks
The main risk is that no partnering agreement is reached for P140 in the timeframe the company has targeted. Funding receipts under the sharing agreement could fall short if the share price weakens, and further dilution is possible. Drug development carries regulatory and clinical uncertainty, and the company's cash balance is modest.
What to watch next
The key milestone is any P140 commercial deal, with US licensing partner Avion Pharmaceuticals described as engaged in constructive discussions. Planned interactions with the US Food and Drug Administration on Kapiglucagon, publication of a P140 scientific manuscript and monthly Lanstead settlements will also be watched. The board has described the priorities as delivering a P140 deal in 2026 and moving Kapiglucagon through its planned development steps, while keeping spending disciplined. Any update on the evaluation of BioAMB and BioCIN would be a further point of interest.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...